Home Stock

Stock Research: Genmab

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Genmab

CPH:GMAB DK0010272202
77
  • Value
    36
  • Growth
    94
  • Safety
    Safety
    71
  • Combined
    89
  • Sentiment
    29
  • 360° View
    360° View
    77
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Genmab A/S is a biotechnology company specializing in antibody therapeutics for cancer treatment. The company operates in the biotechnology industry and creates antibody therapeutics such as DARZALEX, Kesimpta, TEPEZZA, and FASPRO. Genmab operates internationally, with its approved therapies available in various regions. In the last fiscal year, the company had a market cap of $14,027 million, profits of $2,979 million, revenue of $3,122 million, and 2682 employees.

more

ANALYSIS: With an Obermatt 360° View of 77 (better than 77% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock Genmab are very positive. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Genmab. The consolidated Growth Rank has a good rank of 94, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 94% of competitors in the same industry. In addition, the consolidated Safety Rank has a safer rank of 71 which means that the company has a financing structure that is safer than 71% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the consolidated Value Rank has a less desirable rank of 36 which means that the share price of Genmab is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is higher than for 64% of alternative stocks in the same industry. The consolidated Sentiment Rank also has a low rank of 29, which means that professional investors are more pessimistic about the stock than for 71% of alternative investment opportunities. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Growth
Country Denmark
Industry Biotechnology
Size Large
Website genmab.com
Index
OMX C20
NASDAQ
Genmab stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 9-Apr-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
36 18 3 1
Growth
94 42 57 51
Safety
Safety
71 100 98 90
Sentiment
29 48 56 52
360° View
360° View
77 56 51 40
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
28 31 36 39
Opinions Change
56 60 74 53
Pro Holdings
n/a 65 65 68
Market Pulse
11 54 43 41
Sentiment
29 48 56 52
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
36 18 3 1
Growth
94 42 57 51
Safety Safety
71 100 98 90
Combined
89 72 58 41
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
55 11 9 3
Price vs. Earnings (P/E)
11 47 17 10
Price vs. Book (P/B)
49 42 19 8
Dividend Yield
1 1 1 1
Value
36 18 3 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
55 83 75 82
Profit Growth
94 21 28 8
Capital Growth
91 67 88 83
Stock Returns
58 18 22 32
Growth
94 42 57 51
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
26 90 92 89
Refinancing
69 58 71 56
Liquidity
76 92 94 98
Safety Safety
71 100 98 90

Similar Stocks

Discover high‑ranked alternatives to Genmab and broaden your portfolio horizons.

Strabag

VIE:STR
Country: Austria
Industry: Construction & Engineering
Size: X-Large
Full Stock Analysis

Volkswagen VW

GER:VOW
Country: Germany
Industry: Automobile Manufacturers
Size: XX-Large
Full Stock Analysis

Yara International

OSL:YAR
Country: Norway
Industry: Fertilizers & Agricultural Chemicals
Size: X-Large
Full Stock Analysis

Richter Gedeon

BUD:RICHTER
Country: Hungary
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Frequently Asked
Questions

The company has high growth and safe financing but is expensive (low Value Rank) and has low market sentiment. This is a warning that the stock may be too expensive. This is for an experienced growth investor willing to risk overpaying, but only after conducting thorough research on future growth potential.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews